SANTA ROSA, CA – September 29, 2010 – Osseon™ Therapeutics, Inc. an innovative biomedical device company that provides minimally invasive treatments for degenerative bone disease and osteo-traumatic injuries announced today that it has reached a significant milestone in vertebral compression fracture (VCF) treatments using its Osseoplasty System.
Dr. Michael Lyster, Chief Medical Officer of Osseon commented, “Since releasing for commercial use in the US in January 2009 and CE Mark approval in February 2010, we have seen steady growth in physicians utilizing our unique technology to treat patients suffering from VCFs in the U.S. and Europe. By treating our 1,000th patient, we have demonstrated that Osseoplasty is a safe and effective alternative to traditional treatment options. “
Over 125 interventionalists and surgeons have used the Osseoplasty System to treat their patients. Dr. Robert Baldwin, M.D., an Interventional Radiologist at Chandler Hospital in Chandler, Arizona said "The Osseoplasty System is a minimally invasive mechanical device that allows the physician to access the entire vertebral body during a percutaneous vertebral augmentation procedure via a unipedicular approach to treat vertebral compression fractures. The Osseoflex™ Steerable Vertebral Augmentation Needle is very easy to use and allows for the precise delivery of bone cement to stabilize and reduce vertebral compression fractures, which, in turn, alleviates patient suffering due to osteoporosis. I believe the Osseoplasty System represents a significant advancement for treatment of this potentially devastating condition."
John Stalcup, Ph.D., President and CEO of Osseon Therapeutics, said “Osseon is committed to bringing innovative tools and treatments to clinicians. We are also committed to providing safe and effective treatments to patients suffering from osteoporosis and related bone diseases and injuries.”
Osseon Therapeutics currently markets the Osseoflex™ Steerable Vertebral Augmentation Needle and Osseoperm™ Bone Cement for the treatment of vertebral compression fractures. Together, the Osseoplasty System represents an unparalleled procedure for physicians treating degenerative bone disease and osteo-traumatic bone injuries.
ABOUT Osseon Therapeutics, Inc.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon is a registered trademark of Osseon Therapeutics, Inc.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953